Speciality Medicines Ltd
Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals.[1]
- Market Cap ₹ 111 Cr.
- Current Price ₹ 126
- High / Low ₹ 130 / 124
- Stock P/E 12.9
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 34.5 %
- ROE 37.8 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 35.6%
- Debtor days have improved from 96.2 to 60.0 days.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 40.44 | 23.24 | 27.52 | 58.27 | |
| 38.16 | 19.66 | 22.24 | 49.14 | |
| Operating Profit | 2.28 | 3.58 | 5.28 | 9.13 |
| OPM % | 5.64% | 15.40% | 19.19% | 15.67% |
| 0.00 | 0.02 | 0.13 | 0.27 | |
| Interest | 0.03 | 0.35 | 0.62 | 0.51 |
| Depreciation | 0.11 | 0.30 | 0.23 | 0.20 |
| Profit before tax | 2.14 | 2.95 | 4.56 | 8.69 |
| Tax % | 30.84% | 43.05% | 35.53% | 0.92% |
| 1.48 | 1.69 | 2.93 | 8.61 | |
| EPS in Rs | 70.48 | 4.42 | 5.73 | 13.38 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 13% |
| TTM: | 112% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 80% |
| TTM: | 194% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 36% |
| Last Year: | 38% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 0.21 | 3.82 | 5.12 | 6.44 |
| Reserves | 1.72 | 2.05 | 9.95 | 23.98 |
| 1.18 | 3.64 | 2.86 | 5.05 | |
| 2.66 | 3.75 | 4.75 | 4.51 | |
| Total Liabilities | 5.77 | 13.26 | 22.68 | 39.98 |
| 1.91 | 1.69 | 1.47 | 1.97 | |
| CWIP | 0.07 | 0.07 | 0.09 | 0.00 |
| Investments | 0.21 | 0.10 | 0.10 | 0.10 |
| 3.58 | 11.40 | 21.02 | 37.91 | |
| Total Assets | 5.77 | 13.26 | 22.68 | 39.98 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 0.81 | -4.21 | -4.80 | -5.79 | |
| -2.33 | 0.03 | -0.03 | -2.07 | |
| 1.60 | 4.37 | 4.81 | 8.46 | |
| Net Cash Flow | 0.08 | 0.18 | -0.01 | 0.60 |
| Free Cash Flow | -1.28 | -4.29 | -4.83 | -6.40 |
| CFO/OP | 36% | -101% | -66% | -63% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 23.38 | 86.54 | 142.05 | 60.01 |
| Inventory Days | 5.00 | 103.13 | 161.04 | 150.40 |
| Days Payable | 12.29 | 40.36 | 48.33 | 8.39 |
| Cash Conversion Cycle | 16.08 | 149.31 | 254.76 | 202.01 |
| Working Capital Days | -3.25 | 76.49 | 185.42 | 180.21 |
| ROCE % | 52.30% | 37.76% | 34.46% |
Business Profile[1]
Co. is engaged in the marketing and distribution of specialty pharmaceutical formulations, with a focus on high-cost oral and injectable drugs across key therapeutic areas including oncology, immunology, neurology, and rare diseases.